Search the Newsreel

EcoR1 Capital LLC Takes Position in Stoke Therapeutics, Inc. $STOK

EcoR1 Capital LLC acquired 100,000 shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) in the first quarter, a position valued at $3.26 million. Analysts rate STOK a "Moderate Buy" with an average price target of $43, despite the company reporting losses as it develops genetic medicines. …

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates

Stoke Therapeutics announced it will host a webcast and conference call on Monday, August 3, 2026, at 4:30 p.m. ET, to discuss its second quarter 2026 business and financial updates. The company is focused on restoring protein expression using RNA medicine, with its lead …

Stoke Therapeutics Inc (STOK) Cash Flow

This article provides a detailed cash flow statement for Stoke Therapeutics Inc (STOK), covering quarterly and annual data for operating, investing, and financing activities. It presents a comprehensive historical overview of the company's cash flow performance, including net income, operating gains/losses, changes in working …

STOK|Stoke Therapeutics Inc|Price:31.279|Chg%:-0.030

Stoke Therapeutics Inc (STOK) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Stoke Therapeutics Inc (STOK) focusing on its dividend and stock split history. It states that the company has not distributed any dividends over the past five years and shows no forthcoming dividend data. The page also presents current …

Troluce Capital Advisors LLC Buys Shares of 652,800 Stoke Therapeutics, Inc. $STOK

Troluce Capital Advisors LLC has acquired 652,800 shares of Stoke

Does Stoke Therapeutics’ New Genetic Medicine CSO Hire Reframe Its R&D Ambitions for STOK?

Stoke Therapeutics recently appointed Thomas McCauley, Ph.D., as Chief Scientific Officer, bringing over 25 years of R&D and rare disease drug development experience, particularly in genetic and RNA-based medicines. This hire is seen as directionally positive for the company's antisense oligonucleotide programs, including the …

Stoke Therapeutics appoints Thomas McCauley as Chief Scientific Officer

Stoke Therapeutics has appointed Thomas McCauley as its new Chief Scientific Officer. McCauley brings over 25 years of experience in leading R&D teams and translating scientific discoveries into clinical programs, with extensive expertise in novel technology platforms, particularly in rare diseases and mRNA technologies. …

(STOK) and the Role of Price-Sensitive Allocations

This article provides an in-depth analysis of Stoke Therapeutics Inc. (NASDAQ: STOK), highlighting weak near and mid-term sentiment despite a positive long-term outlook. It details AI-generated trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal …

Can Stoke Therapeutics (STOK) Be A Bargain As Its New CSO Reshapes The Story?

Stoke Therapeutics (STOK) has garnered investor attention following the appointment of Thomas McCauley as Chief Scientific Officer, an experienced leader in genetic medicines. Despite a recent share price decline over 30 days, the company has shown strong longer-term momentum, with one- and three-year total …

Stoke Therapeutics Chief Scientific Officer Thomas McCauley files initial beneficial ownership statement

Stoke Therapeutics' Chief Scientific Officer, Thomas McCauley, has filed an initial Form 3, which is a statement of beneficial ownership. The filing is dated July 13, 2026, and officially names McCauley in his role. This news brief was generated by AI using information released …

Is Stoke Therapeutics’ (STOK) New CSO Appointment Reframing Its Genetic Medicines Innovation Story?

Stoke Therapeutics appointed Thomas McCauley, Ph.D., as Chief Scientific Officer, a move that is supportive of their R&D ambitions but doesn't materially alter the near-term risks associated with the EMPEROR Phase 3 data and regulatory timeline. McCauley's extensive experience in genetic medicines is expected …

Form 4 Stoke Therapeutics Inc For: 17 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Stoke Therapeutics Inc. dated July 17th. It provides the title of the filing and mentions the company's stock symbol, STOK. The piece is brief and primarily serves as an announcement of the SEC …

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - July 16, 2026

Stoke Therapeutics, Inc. announced inducement grants of stock options to eight new employees including its newly-appointed Chief Scientific Officer, Thomas McCauley. These grants, made effective July 15, 2026, are in accordance with Nasdaq Listing Rule 5635(c)(4) and serve as a material inducement to their …

Stoke Therapeutics (STOK) awards 225,000 stock options to Chief Scientific Officer

Stoke Therapeutics (STOK) has awarded its Chief Scientific Officer, Thomas McCauley, 225,000 stock options at an exercise price of $29.91 per share, expiring on July 14, 2036. The options will vest over time, with 1/4 vesting on July 15, 2027, and the remainder vesting …

Stoke Therapeutics (STOK) CSO Thomas McCauley files initial insider report

Stoke Therapeutics (STOK) Chief Scientific Officer Thomas McCauley has filed an initial insider report (Form 3), designating him as an executive officer but not a director or 10% owner. The filing, accepted by the SEC on July 17, 2026, indicates no stock transactions or …

Stoke Therapeutics (STOK) director gifts 303,190 options to trust

Stoke Therapeutics director Seth Loring Harrison gifted 303,190 stock options to the East Pillar 2026 Irrevocable Trust on July 16, 2026. These options are fully vested with exercise prices between $10.90 and $40.37, expiring from 2029 to 2036, and were transferred without consideration, exempt …